D-dimer before chemotherapy might predict venous thromboembolism
- 1 April 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Blood Coagulation & Fibrinolysis
- Vol. 20 (3), 170-175
- https://doi.org/10.1097/mbc.0b013e32831bc2de
Abstract
To see whether D-Dimer levels can identifying patients at high risk of venous thrombotic events and establish the best benefit/risk-of-bleeding ratio. Current guidelines do not recommend routine prophylaxis against venous thromboembolism (VTE) in cancer patients receiving chemotherapy, but the risk increases about 6.5-fold because of this treatment. D-dimer was measured at baseline in 124 cancer patients scheduled for their first chemotherapy. VTE events, including symptomatic episodes of deep vein thrombosis or pulmonary embolism or both, were recorded during the first 6 months of therapy, and asymptomatic deep vein thrombosis was revealed by compression ultrasonography at baseline and after 90 and 180 days. During follow-up, there were 11 episodes of VTE (8.9%). Mean D-dimer values were higher in patients with VTE (2195 ± 1382 vs. 695 ± 1039 ng/ml, (P < 0.001). On grouping D-dimer values in tertiles, only 2.4% (confidence interval, 0.9–5.7%) in the first (650 ng/dl) (P = 0.003). The VTE-free interval was significantly shorter in the third tertile than in the first (P = 0.0218, log–rank test; relative risk for third vs. first tertile, 11.0; 95% confidence interval, 1.4–81.3; P = 0.0033). Multivariate analysis found that only baseline D-dimer concentrations were correlated with the subsequent development of VTE. Baseline D-dimer values in cancer patients scheduled for chemotherapy might be used to select those at low risk of VTE, most likely to be safe without prophylaxis.Keywords
This publication has 23 references indexed in Scilit:
- Prevention of Venous ThromboembolismSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004
- Symptomatic Venous Thromboembolism in Cancer Patients Treated With ChemotherapyArchives of Internal Medicine, 2004
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis.Archives of Internal Medicine, 2002
- Clinical Utility of a Rapid Whole-Bloodd-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1999
- D-Dimer Testing in the Diagnosis of Acute Venous ThromboembolismThrombosis and Haemostasis, 1999
- Trends in the Incidence of Deep Vein Thrombosis and Pulmonary EmbolismArchives of Internal Medicine, 1998
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.Journal of Clinical Oncology, 1991